Korean drugmaker Celltrion has paid KRW 1 billion ($700,000) to access Pinot Bio’s antibody-drug conjugate (ADC) linker-payload technology. The PINOT-ADC platform, comprising of an independent drug and linker technology, overcomes the resistance limitations of existing ADC drugs, according to developer Pinot Bio. As such, fellow Korean firm Celltrion has tapped up the technology, forging a deal for up to 15 ADC candidates targeting solid tumor cancers using the platform. According to the Korea Biomedical Review, on top of the KRW…